Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Dianthus Therapeutics (NASDAQ:DNTH) had its target price raised by Robert W. Baird from $50.00 to $67.00 in a report released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts also recently weighed in on DNTH. Wedbush upped their price target on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday, August 21st. William Blair assumed coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $60.67.

Dianthus Therapeutics Stock Performance

DNTH opened at $37.86 on Tuesday. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $38.59. The firm has a market cap of $1.22 billion, a P/E ratio of -11.65 and a beta of 1.46. The business’s fifty day moving average is $22.65 and its 200-day moving average is $20.43.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. On average, research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 8.15% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently bought and sold shares of DNTH. Vestal Point Capital LP grew its holdings in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. raised its holdings in Dianthus Therapeutics by 53.6% in the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after buying an additional 1,000,333 shares during the last quarter. Octagon Capital Advisors LP boosted its position in Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock worth $42,478,000 after buying an additional 231,500 shares during the period. Alliancebernstein L.P. grew its holdings in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after acquiring an additional 149,200 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Dianthus Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company’s stock valued at $23,607,000 after acquiring an additional 136,314 shares during the period. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.